Ad5-EBOV(Ebola)

Adenovirus Type 5 Vector Based Ebola Virus Disease Vaccine

The candidate Adenovirus Type 5 (Ad5) Vector Based Ebola Virus Disease Vaccine (Ad5-EBOV) 

is developed by Beijing Institute of Biotechnology and Tianjin CanSino Biotechnology Inc. The 

Ad5-EBOV is a recombinant replication defective human Ad5 vector based vaccine expressing 

Ebola virus glycoprotein (GP) (Guinea, 2014). It is manufactured through cell amplification, 

purification, formulation with stabilizer and lyophilization. The final product is lyophilized white 

powder. Humeral and cellular responses could be caused after vaccination to prevent Ebola 

virus disease.